Investigating the effects of a supported self-management pathway in people who have completed treatment for breast cancer

PRAGMATIC: Patients' experiences of a supported self-management pathway in breast cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN10777283

Enrollment

110

Registered

2020-02-17

Start date

2020-02-10

Completion date

Unknown

Last updated

2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer Cancer Malignant neoplasm of breast

Interventions

The SSM pathway in breast cancer is delivered by the healthcare professionals usually via workshops or a one-to-one appointment. The aim is to provide patients who have finished their hospital treatme

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Completed hospital treatment for breast cancer and about to join the supported self-management pathway 2. Attended end-of-treatment appointment and supported self-management workshop/one-to-one consultation 3. Able to read and understand English 4. Willing and able to provide consent 5. Aged 18 years or over

Exclusion criteria

Exclusion criteria: 1. Currently inpatient 2. Acutely distressed for any reason 3. From a hospital outside the Surrey and Sussex Cancer Alliance 4. Do not speak/understand English and have no one to interpret/translate

Design outcomes

Primary

Measure	Time frame
1. Physical, social, emotional, and functional well-being assessed using the Functional Assessment of Cancer Therapy-Breast (FACT-B) questionnaire at baseline and 3, 6, 9 and 12 months 2. Breast cancer concerns assessed using the FACT-B sub-scale at baseline and 3, 6, 9 and 12 months 3. Impact of cancer and its treatments on everyday life assessed using the Patient Roles and Responsibilities Scale (PRRS) at baseline and 3, 6, 9 and 12 months 4. Mental wellbeing assessed using the General Health Questionnaire-12 (GHQ-12) at baseline and 3, 6, 9 and 12 months 5. Health-related quality of life assessed using the EuroQol-5D-5L (EQ5D-5L) scale at baseline and 3, 6, 9 and 12 months 6. Self-efficacy assessed using the General Self-Efficacy Scale (GSE) at baseline and 12 months 7. Patient's use of and assess to NHS services assessed using a service use questionnaire at 3, 6, 9 and 12 months 8. Participant's views about the supported self-management pathway assessed by interview at baseline and 3, 6, 9 and 12 months	—

Measure

Time frame

1. Physical, social, emotional, and functional well-being assessed using the Functional Assessment of Cancer Therapy-Breast (FACT-B) questionnaire at baseline and 3, 6, 9 and 12 months 2. Breast cancer concerns assessed using the FACT-B sub-scale at baseline and 3, 6, 9 and 12 months 3. Impact of cancer and its treatments on everyday life assessed using the Patient Roles and Responsibilities Scale (PRRS) at baseline and 3, 6, 9 and 12 months 4. Mental wellbeing assessed using the General Health Questionnaire-12 (GHQ-12) at baseline and 3, 6, 9 and 12 months 5. Health-related quality of life assessed using the EuroQol-5D-5L (EQ5D-5L) scale at baseline and 3, 6, 9 and 12 months 6. Self-efficacy assessed using the General Self-Efficacy Scale (GSE) at baseline and 12 months 7. Patient's use of and assess to NHS services assessed using a service use questionnaire at 3, 6, 9 and 12 months 8. Participant's views about the supported self-management pathway assessed by interview at baseline and 3, 6, 9 and 12 months

—

Secondary

Measure	Time frame
There are no secondary outcome measures	—

Countries

England, United Kingdom

Contacts

Public ContactLucy Matthews

l.matthews@sussex.ac.uk+44 (0)1273 877919

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026